Vertex Pharma (VRTX): Updating Estimates But No PT Change - Baird

November 29, 2016 6:42 AM EST
Get Alerts VRTX Hot Sheet
Price: $81.37 +0.57%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VRTX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) after tweaking estimates. Kalydeco and Orkambi sales estimates changed with of third-quarter financial results.

There do not appear to be growth drivers for Kalydeco outside of a longshot approval in residual function mutations and the analyst is taking Kalydeco sales down modestly. However, Orkambi sales could be helped by expansion in France, which is not factored into reported sales numbers.

The net is an unchanged price target at $115.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $86.90 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change

Related Entities

Robert W Baird, Earnings

Add Your Comment